Wayne Kuznar

Authored Items
ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies
In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Leukemia
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Prostate Cancer
CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Multiple Myeloma
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Breast Cancer
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Lung Cancer
Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Lymphoma
The Hematology Pipeline Features New Immune Therapies, and Targeted Agents
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Multiple Myeloma
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Multiple Myeloma
Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia
AVBCC Sixth Annual Conference: The Evolution of Value-Based Cancer Care
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Conference Correspondent
Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Immunotherapy
Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Personalized Medicine
Specialty Pharmacies Add Value in the Management of Cancer Drugs
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Specialty Pharmacy
Practice Transformation Essential to the Oncology Care Model
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Integrated Care Models
PhRMA’s Perspective on Value-Driven Healthcare
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Quality Measures Are Key to Supporting Drug Value
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
ASCO CEO Addresses Quest for Value in Cancer Care
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Cost-Savings Measures Will Dot the Oncology Landscape
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Value-Based Oncology Management and Outcomes-Based Contracting
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Cost, Access, and Delivery Challenge New Oncology Drug Options
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Value in Oncology
Employers Look to Manage the Benefits of Specialty Pharmacy
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Employers’ Perspective
ASCO President Addresses Quality Care Through Collective Wisdom
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Online First, Value in Oncology
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Adding the BCL-2 Inhibitor Venetoclax to Treatment Regimen Promising in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Novel Chimeric Monoclonal Antibody Improves Survival in Advanced Gastric Cancers
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Novel Vaccine Induces Immunologic Responses in Patients with Acute Myeloid Leukemia
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies, Online First
Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Lung Cancer
Nivolumab plus Ipilimumab Combination Promotes Durable Responses in Advanced Lung Cancer
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Lung Cancer
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Bladder Cancer
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Leukemia
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
In the News: August 2016 in Multiple Myeloma
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick, Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Care Pathway for NSCLC Cuts Chemotherapy Cost
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Health Economics
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Nivolumab Makes Headwinds into Liver Cancer
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
ASP plus 6% Will Fall by the Wayside, but What Are the Alternatives?
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Payment Reform
Monthly Care Management Payments Called “Win-Win-Win” Reform
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Payment Reform
Enhanced Reimbursement for Oncology Services Pays for Patient-Centered Care
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Payment Reform
The Push Toward Value-Based Payment for Oncology
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Payment Reform
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Personalized Medicine
Immunotherapy with PD-1 Inhibitors the Newest Break­­through in Hodgkin Lymphoma
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Lymphoma
The Hematology Pipeline Is Abundant
Wayne Kuznar, Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Health Economics
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Health Economics
Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia
CAR-T Achieves High Rate of Remission in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Breast Cancer
Federal Spending on Cancer Research and Access to Care Woefully Inadequate
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Health Economics
Payment Reform Key to Value-Based Cancer Care
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Value in Oncology
2014 Oncology Pipeline Looks Impressive
Caroline Helwick, Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Emerging Therapies
Patients with Cancer Are Not Asking for Costly, Excessive Treatments
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Health Economics
Even When Adjusting for Improved Survival, Newer Cancer Drugs More Expensive Than Older Ones
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Health Economics
Should Oncologists Consider Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Health Economics
Upfront Docetaxel Markedly Improves Survival in Metastatic Prostate Cancer, at Reduced Cost
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Prostate Cancer
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Lung Cancer
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Web Exclusive
Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Web Exclusive
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Web Exclusive
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Health Economics
Promising Drugs in the Pipeline for Leukemia and Myelodysplastic Syndromes
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia
Physicians Must Consider the Financial Burden of Allogeneic Transplants
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Health Economics
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Health Economics
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Health Economics
Rituximab Infusions Costlier When Given in the Hospital
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Health Economics
Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia
Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia
Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia
Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Personalized Medicine
Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Lymphoma
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Conference Highlights ASH
New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Lipids
Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Health Economics
Future of Healthcare Reform: Expect New Payment and Delivery Models
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Health Economics
GLP-1 Agonists May Protect Patients with Diabetes from Heart Failure
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Emerging Therapies
Look AHEAD: Lifestyle Intervention Cost-Effective in Overweight Patients with Type 2 Diabetes
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Health Economics
SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights in Emerging Therapies
Mammography Screening Rates Enhanced by Copay Elimination
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Essential Health Benefits, Comparative Effectiveness Research, Payment Models All Play a Role in the ACA
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Use of High-Cost Diagnostic Tests for Lung Cancer Surveillance Rising
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Poor Adherence to Oral Cancer Drugs a Growing Concern
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Causes of Hospital Readmissions of Patients with Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Dabrafenib Shows Promising Results in Patients with Stage IV NSCLC
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Lung Cancer
Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Lung Cancer
Current Treatment of Advanced NSCLC Requires Testing for Driver Mutations
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Lung Cancer
New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Breast Cancer
Lack of Knowledge Prevents Men with Early-Stage Prostate Cancer from Choosing Active Surveillance
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Prostate Cancer
New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Prostate Cancer
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Drug Therapy
ASCO President Highlights Bridges to Conquer Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Health Economics
Cancer Drug Pipeline Is Bustling
Caroline Helwick, Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue in Incretin Therapies
Low-Cost Phone Intervention Helps with Weight Loss, Glycemic Control
Wayne Kuznar
Other in Lipids
Symptomatic hypoglycemia increases risk of cardiovascular events, death in type 2 diabetes
Wayne Kuznar
Other in Lipids
Weight Loss Intervention Fails to Reduce Cardiovascular Events in Type 2 Diabetes, but Has Positive Effect on Other Measures
Wayne Kuznar
Other in Lipids
Achieving glucose, blood pressure, and lipid targets improving among diabetic patients, but there’s still long way to go
Wayne Kuznar
Other in Lipids
Cardiovascular data confirm metformin over sulfonylurea as initial treatment choice in type 2 diabetes
Wayne Kuznar
Other in Cardiometabolic Health
Does insulin increase the risk of type 2 diabetes-related complications?
Wayne Kuznar
Other in Lipids
NIH Research Funding Cuts Would Have Devastating Impact on Hematology
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Health Economics
New Targeted Agent Shows Significant Success in Treating Refractory Form of AML
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Leukemia
Selective JAK Inhibitor Cost-Effective Option for Patients with Myelofibrosis
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Health Economics
Combined Chemoradiation Cost-Effective in Younger Patients with Primary CNS Lymphoma
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Health Economics
New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Leukemia
Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Leukemia
Alternatives to “7 + 3” Induction Therapy for AML Are Emerging
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Leukemia
PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue in Lymphoma
Measuring Coronary Calcium in Patients with Type 2 Diabetes Improves CVD Risk Assessment
Wayne Kuznar
Other in Lipids
CABG Surgery Outcomes Superior to PCI and Cost-Effective in Patients with Diabetes and Multivessel CAD
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Health Economics
Probiotic Reduces LDL Cholesterol Level
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Web Exclusive
Not All Omega-3 Fatty Acids Have the Same Effects on Lipids
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Web Exclusive
Interventions for Cardiovascular Risk Reduction in Type 2 Diabetes Must Be Multifactorial
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health
GLP-1 Agonism Holds Promise for Preventing Macrovascular Disease in Type 2 Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Emerging Therapies
Control of 4 Risk Factors Would Slash CHD Rate in Diabetes by Half
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health
Several Antihypertensive Drug Combinations Increase the Risk for Incident Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health
Alternative Anticoagulants to Warfarin Reduce Vascular Risk in Patients with NVAF
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health
Behavioral Interventions Can Result in Weight Loss
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Obesity/Overweight
New Hypertension Guidelines Will Be Strictly Evidence-Based
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Hypertension
Lipid Therapy Update: HDL Therapies Falling Short, Promising LDL Agents, 2 Potential Treatments for Familial Hypercholesterolemia
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Lipid Disorders
Weight loss from lifestyle changes does not reduce adverse cardiovascular outcomes in patients with type 2 diabetes
Wayne Kuznar
Other in Lipids
New ADA-EASD Position Statement on Managing Hyperglycemia in Type 2 Diabetes favors Individualized Approach
Wayne Kuznar
Other in Lipids
Mounting Evidence that DPP-4 Inhibitors may Reduce Cardiovascular Risk
Wayne Kuznar
Other in Lipids
Diabetes Drug Pipeline: Promising Agents in Late Stages of Development
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies
New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies
The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies
Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Lipids
Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Lipids
1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Lipids
Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Lipids
DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Incretin Therapies
Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Health Economics
Paying Patients to Change Their Health Behavior Is Effective
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Health Economics
Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Lipids
Diabetes Rates Surging Among American Youth
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health
The Diabetes Epidemic Is Like a Tsunami Hitting in Waves
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Health Economics
Incretin Therapies Lower Cardiovascular Risk Score
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health
Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health
The Diabetes Epidemic Is Like a Tsunami Hitting in Waves
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Health Economics
Incretin Therapies Lower Cardiovascular Risk Score
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health
Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health
Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Lipids
Diabetes Rates Surging Among American Youth
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health
Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Health Economics
Paying Patients to Change Their Health Behavior Is Effective
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Health Economics
DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Incretin Therapies
1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Lipids
Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Lipids
Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Lipids
Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Lipids
Diabetes Drug Pipeline: Promising Agents in Late Stages of Development
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies
The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies
Novel Basal Insulin LY2605541 Lowers Blood Glucose, Enhances Weight Loss
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies
New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Renal-Cell Carcinoma
Family History of Cancer/Genetic Counseling Often Lacking for Patients First Presenting with Malignancy
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Personalized Medicine
Cancer Therapies in Short Supply Prompt a Response at the Federal Level
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Health Economics
Non–Small-Cell Lung Cancer Testing Can Be Offered Routinely in Community Hospitals
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Lung Cancer
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Lung Cancer
Enzalutamide Extends Survival, Improves QOL in Advanced Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer
Abiraterone Before Chemotherapy a Successful Strategy in Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer
Agent that Targets Heat Shock Protein Shows Activity in Castration-Resistant Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer
A Promising New Gene Test to Differentiate Between Aggressive and Indolent Disease
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Renal-Cell Carcinoma
The Oncology Drug Pipeline Robust with Novel Agents
Caroline Helwick, Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Pipeline
Monoclonal Antibody Produces Powerful Reductions in LDL Cholesterol
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Lipid Disorders
Low-Potency Statins Initiated in High-Risk Patients in a Managed Care Setting
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Lipid Disorders
New Drug Therapies for Difficult-to-Control Atrial Fibrillation
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Atrial Fibrillation
Blood Assay for Galectin-3 Identifies Heart Failure Risk of Patients in the Community Setting
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Heart Failure
Levels of Gene Expression a New Noninvasive Way to Identify Obstructive CAD
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health
Triple-Antiplatelet Therapy Equal to Double-Dose Dual Therapy After Percutaneous Coronary Intervention
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health
Single-Agent Oral Regimen as Effective as Current Standard for Pulmonary Embolism, Less Bleeding
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health
Lipid-Lowering Drug Pipeline: There Is Life After Statins
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Lipid Disorders
New Oral Anticoagulants Show Superior Efficacy versus Warfarin, and No Need for Monitoring
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Atrial Fibrillation
IMMEDIATE: Early Use of Inexpensive Glucose-Insulin- Potassium Solution Can Prevent Cardiac Arrest in ACS
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Acute Coronary Syndrome
Value of New Anticoagulants in Acute Coronary Syndrome Still Unclear
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Acute Coronary Syndrome
Consider Combination Therapy for Patients with Low- and High-Risk Hypertension
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Hypertension
Blood Glucose Testing a Significant Contributor to Pharmacy Costs in Patients Using Insulin
Wayne Kuznar
Other in Health Economics, Conference Highlights ADA
Diabetes Prevention with Metformin Is Cost-Saving for Persons at High Risk
Wayne Kuznar
Other in Health Economics, Conference Highlights ADA
Adding Saxagliptin to Metformin Improves Glycemic Control Over Uptitrating Metformin Dose
Wayne Kuznar
Other in Drug Therapy, Conference Highlights ADA
Treatment Satisfaction Highest for Diabetic Patients Taking Only Oral Medications
Wayne Kuznar
Other in Drug Therapy, Conference Highlights ADA
Insulin Inappropriately Discontinued in Many Type 2 Diabetes Patients After Hospitalization
Wayne Kuznar
Other in Drug Therapy, Conference Highlights ADA
Education, Counseling Associated with Improved Clinical Outcomes in Type 2 Diabetes
Wayne Kuznar
Other in Conference Highlights ADA, Lipids
Medical Food Improves Symptoms of Diabetic Neuropathy
Wayne Kuznar
Other in Conference Highlights ADA, Lipids
Artificial Pancreas Passes Test in Patients with Type 1 Diabetes
Wayne Kuznar
Other in Conference Highlights ADA, Lipids
Anti-VEGF Antibody Injections Improve Vision in Diabetic Macular Edema
Wayne Kuznar
Other in Conference Highlights ADA, Lipids
Cutting-Edge Data Presented at ADA 2011 Highlight the Diabetes–Cardiovascular Disease Link
Wayne Kuznar
September/October 2011 Volume 4, Number 6 in Conference Highlights ADA
Get Ready for the New Era of “Genomic Chaos” in Cancer Care
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Health Economics
Patients Want to Discuss Cost of Care, Oncologists Often Avoid It
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Health Economics
Economic Recession Affects Rates of Cancer Incidence and Treatment
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Health Economics
Medicaid Reimbursement for Cancer Screening Lags Inflation
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Health Economics
Multiple Myeloma Treatments Are Moving Rapidly from Bench to Bedside
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Multiple Myeloma
Cabozantinib Shows Dramatic Effects on Bone Metastases in Advanced Prostate Cancer
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue in Prostate Cancer
Emerging Drugs for COPD Target Lung Function, Inflammation, Smooth-Muscle Cells in Airways
Wayne Kuznar
Other in Annual Index
Patients with COPD and Their Caregivers Are Satisfied with Nebulizer Therapy
Wayne Kuznar
Other in Annual Index
Total Annual COPD Costs Top $4000 per Patient
Wayne Kuznar
Other in Annual Index
Burden of COPD on Older Employees Is Substantial
Wayne Kuznar
Other in Annual Index
COPD Treatment Complexity Affects Adherence, Resource Utilization
Wayne Kuznar
Other in Annual Index
COPD Alliance Aims for Better Recognition and Care of COPD
Wayne Kuznar
Other in Annual Index
Expect Widespread Adoption of P4P as Healthcare Spending Increases
Wayne Kuznar
Other in Annual Index
Selecting an Inhalation Device for COPD Should Consider Peak Flow Rates, Patient Satisfaction
Wayne Kuznar
Other in Annual Index
Performance, Preference Vary for COPD Inhalers
Wayne Kuznar
Other in Annual Index
New Developments in Aerosol Delivery Aim to Improve Therapeutic Efficacy
Wayne Kuznar
Other in Annual Index
Dry Powder Inhalers Compared for Correct Use, Ease of Handling: Breezhaler versus HandiHaler
Wayne Kuznar
Other in Annual Index
Investigational Anticholinergic Achieves Early Bronchodilation
Wayne Kuznar
Other in Annual Index
Novel PDE 4 Inhibitor Cuts COPD Exacerbations
Wayne Kuznar
Other in Annual Index
Roflumilast Improves Lung Function Independent of Inhaled Corticosteroids
Wayne Kuznar
Other in Annual Index
Systemic Effects of COPD Linked to Many Comorbidities, Affect Treatment Decisions, Increase Costs
Wayne Kuznar
Other in Annual Index
Worsening Symptoms, Lung Function Precede COPD Exacerbations
Wayne Kuznar
Other in Annual Index
Heading Off Exacerbations in COPD Is Crucial
Wayne Kuznar
Other in Annual Index
First Acute COPD Exacerbation a Significant Risk for Death within 4 Years
Wayne Kuznar
Other in Annual Index
Novel Selective Beta-Agonist Improves Lung Function in COPD: Preliminary Analysis
Wayne Kuznar
Other in Annual Index
Chest 2010 Explores State-ofthe- Art Management of COPD and Treatments on the Horizon
Wayne Kuznar
Other in Annual Index
Healthcare Reform Must Include Multiple Components
Wayne Kuznar
Other in Meeting Highlights, Web Exclusive
Bustling Pipeline for Diabetes and Its Metabolic Consequences
Wayne Kuznar
July/August 2008, Vol 1, No 6 in Meeting Highlights
Healthcare Reform Must Include Multiple Components
Wayne Kuznar
Other in Health Reform, Web Exclusive
FDA WATCH
Wayne Kuznar, Nirav R. Shah, MD,MPH, F. Randy Vogenberg, RPh, PhD
February/March 2009, Vol 2, No 2 in FDA Approvals, News & Updates, Perspectives
Bustling Pipeline for Diabetes and Its Metabolic Consequences
Wayne Kuznar
July/August 2008, Vol 1, No 6 in Meeting Highlights
The Antiplatelet Drug Pipeline: Some Promising Candidates
Wayne Kuznar
November/December 2008, Vol 1, No 9 in Meeting Highlights, Conference Highlights AHA
An Overview of Cholesterol Management
Robyn A. Burns Schaiff, PharmD, BCPS, Wayne Kuznar, Richard M. Moe, MD, PhD, Daniel W. Krichbaum, PharmD
November/December 2008, Vol 1, No 9 in Clinical
The Cardiovascular Pipeline: ACC 2010 Features Late-Stage Drugs
Wayne Kuznar
March/April 2010, Vol 3, No 2 in Pipeline
Cardiology Pipeline Is Promising: AHA 2009
Wayne Kuznar
January/February 2010, Vol 3, No 1 in Industry Trends
The Cardiology Pipeline
Wayne Kuznar
Other in Pipeline, Web Exclusive
Diabetes Pipeline: New Strategies Emerging for Glycemic Control
Wayne Kuznar
Other in Pipeline, Web Exclusive
Last modified: September 6, 2013
  • Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME